Omnicell's stock plummeted 14.99% during intraday trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.
The healthcare technology provider reported adjusted earnings per share of $0.40 for Q4 2025, missing the analyst consensus estimate of $0.50. While quarterly revenue showed a slight increase, the company posted a GAAP net loss of $2 million, reversing from a profit in the prior-year period.
Investors reacted negatively to both the earnings miss and the company's outlook for fiscal year 2026, which includes adjusted EPS guidance of $1.65 to $1.85, below the consensus estimate of $1.88. The significant selloff reflects disappointment with the quarterly performance and future earnings projections.